Filing Flows › Lifecore Biomedical (LFCR) › Q1 FY27 › vs Q1 FY26
Lifecore Biomedical (LFCR) Q1 FY27 vs Q1 FY26 (year over year)
Lifecore Biomedical's revenue fell $5.8M (-19%) from $31.1M in Q1 FY26 to $25.3M in Q1 FY27. The biggest changes: CDMO −$4.0M (-18%); HA manufacturing −$1.8M (-19%).
Lifecore Biomedical, Q1 FY27: revenue $25.3M (-19% year over year), operating margin -3.5%, net loss $40.1M, operating cash flow $6.9M. The chart draws each line against Q1 FY26, the increases inside each band.
Margins
| Q1 FY27 | Q1 FY26 | Change | |
|---|---|---|---|
| Free cash flow margin | 23.8% | 0.1% | +23.7 pts |
Every line
| Line | Q1 FY27 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| CDMO | $17.8M | $21.7M | −$4.0M | -18% |
| HA manufacturing | $7.5M | $9.4M | −$1.8M | -19% |
| Revenue | $25.3M | $31.1M | −$5.8M | -19% |
| Net loss | $40.1M | $10.0M | $30.1M | +301% |
| Costs & expenses | $65.4M | $41.1M | $24.3M | +59% |
| Operating costs | $26.2M | $34.2M | −$8.0M | -23% |
| Interest & other, net | $39.1M | $6.6M | $32.5M | +494% |
| Income tax | $51K | $333K | −$282K | -85% |
| Cost of revenue | $18.5M | $23.3M | −$4.8M | -21% |
| Research & development | $1.4M | $2.0M | −$542K | -28% |
| SG&A | $6.3M | $8.9M | −$2.6M | -29% |
| Operating cash sources | $47.0M | $11.8M | $35.3M | +300% |
| Depreciation | $2.4M | $2.0M | $429K | +22% |
| Share-based compensation | $1.7M | $2.4M | −$677K | -28% |
| Working capital & other | $42.9M | $7.4M | $35.5M | +481% |
| Net loss absorbed | $40.1M | $10.0M | $30.1M | +301% |
| Operating cash flow | $6.9M | $1.8M | $5.2M | +294% |
| Free cash flow (OCF − capex) | $6.0M | $25K | $6.0M | 241× |
| Capital expenditures | $912K | $1.7M | −$825K | -47% |
Questions
How much did Lifecore Biomedical's revenue grow year over year in Q1 FY27?
Lifecore Biomedical's revenue fell $5.8M (-19%) from $31.1M in Q1 FY26 to $25.3M in Q1 FY27.
What drove Lifecore Biomedical's revenue change in Q1 FY27?
CDMO −$4.0M (-18%); HA manufacturing −$1.8M (-19%).